Chronic Hepatitis Delta clinical trials

Explore recruiting chronic hepatitis delta clinical trials.

Recruiting chronic hepatitis delta studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Hepatitis Delta trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.

Italy, Romania, Germany, Bulgaria

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Belgium, Hungary, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

Bulgaria

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection

Bulgaria, Romania, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Austria, Italy, Czechia, Romania, Sweden, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Czechia, Austria, Spain, Romania, Germany, Italy +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

Chronic Hepatitis Delta trials by city

Chronic Hepatitis Delta in Toronto Chronic Hepatitis Delta in Vancouver Chronic Hepatitis Delta in Montreal Chronic Hepatitis Delta in Calgary Chronic Hepatitis Delta in Edmonton Chronic Hepatitis Delta in Ottawa Chronic Hepatitis Delta in Winnipeg Chronic Hepatitis Delta in Quebec City Chronic Hepatitis Delta in Hamilton Chronic Hepatitis Delta in Kitchener Chronic Hepatitis Delta in London Chronic Hepatitis Delta in Halifax Chronic Hepatitis Delta in New York Chronic Hepatitis Delta in Los Angeles Chronic Hepatitis Delta in Chicago Chronic Hepatitis Delta in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease